The Covid-19 pandemic has affected adult vaccination rates against other diseases.Despite the success of immunization against coronavirus, especially among the adult population, the truth is a health crisis exacerbated already low adult vaccination rates.
That’s according to a report prepared by Iqvia and funded by pharmaceutical company GlaxoSmithKline (GSK). According to the consultant’s calculations, 100 million fewer injectable doses between 2021 and 2022 This is higher than expected given the increase in vaccination rates between 2013 and 2020.
Immunizations against diseases such as influenza, hepatitis B or shingles have been The annual growth rate was 8.9%. In fact, 2020 recorded a peak injection of 400 million doses. However, this drops to 7.9% when doses injected between 2013 and 2019 are taken into account.
Vaccine doses administered worldwide.
The consultancy analyzed two possible scenarios, considering the aforementioned growth rate of -8.9% for the 2013-2020 period and 7.9% for the 2013-2019 period.
Analyzing the Phase 1 data, Iqvia calculated that they had discontinued the drug 119 million doses. In other words, if the growth rate of 8.9% is maintained in both 2021 and 2022, the above-mentioned number of vaccines can be injected.
(Spain takes up to six years to fund a new vaccine)
The second scenario considers the growth rate between 2013 and 2019 (7.9%).If they are maintained, they are managed 80 million doses farther.
Using these calculations, Iqvia estimates that between 2021 and 2022, the average dose not injected due to the impact of the Covid-19 pandemic will reach 100 million vaccines.
Vaccination rates are down
In 2021, 363 million doses of the vaccine will be administered, and in 2022, 351 million doses will be administered.That is, between 2020 and 2022 Vaccination rates down 12%according to data collected by Iqvia.
363 million doses registered in 2021 and 351 million doses registered in 2022 represent 16.2 doses per 100 adults worldwide. This figure contrasts with the coronavirus vaccination rate at the end of 2022: 132 doses per 100 people (primary vaccinations for adults and children are considered, booster vaccines are not included, so this figure may only be higher among adults since the campaign High) are more successful than minors).
vaccine spending
The report prepared by Iqvia also analyzed vaccine spending. worldwide, The program accounts for only 2% of drug spending. By region, North America will spend the most money on the purchase of antigens: 1.1% in 2022. for its part, Europe Investments accounted for 0.7% of total spending on pharmaceuticals.
While vaccine spending increased slightly in the years leading up to the pandemic, the reality is that vaccine spending has declined over the past two years.the situation is like this North America. In 2019 and 2020, it allocated 1.3%, and in 2022 it will reach the aforementioned 1.1%.
(Science takes a giant step toward a universal flu vaccine: Here’s the revolutionary drug)
But this situation did not appear in Europe, and countries increased their expenditure on antigens. Investments thus accounted for 0.4% of total healthcare spending in 2019. Rise to 0.7% in 2022. It remains at 0.6% in 2020 and 2021.
The consultation also includes an analysis of vaccine spending in some countries. Among them, Spain. The figures in the report show that my country’s investment in antigens accounts for 0.1% of the total medical expenditure.In stark contrast to the 1.7% achieved Germany.